DanaMeredithChaseMDMD, FACOG(She/Her)
Obstetrics & Gynecology • Los Angeles, CAGynecologic Oncology
Associate Professor, Obstetrics and Gynecology
Dr. Chase is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Office
200 UCLA Medical Plz Ste 220
Los Angeles, CA 90095Phone+1 310-794-7274Fax+1 520-519-7910- Is this information wrong?
Summary
- Dr. Dana Chase is a Gynecologic Oncologist with the David Geffen School of Medicine at UCLA. She received her medical degree, residency and fellowship from University of California Irvine School of Medicine and has been in practice as a Gynecologic Oncologist since 2011. She speaks Spanish fluently. She specializes in gynecologic cancers and has performed over 1500 robotic surgeries. She is a clinical trial investigator and has special interest in chemotherapy for ovarian, cervical and/or uterine cancers.
Education & Training
University of California (Irvine)Fellowship, Gynecologic Oncology, 2007 - 2011- University of California (Irvine)Residency, Obstetrics and Gynecology, 2003 - 2007
University of California, Irvine, School of MedicineClass of 2003
Certifications & Licensure
AZ State Medical License 2011 - 2026
CA State Medical License 2005 - 2025- American Board of Obstetrics and Gynecology Obstetrics & Gynecology
- American Board of Obstetrics and Gynecology Gynecologic Oncology
Awards, Honors, & Recognition
- Fellow (FACOG) American Congress of Obstetricians and Gynecologists
Clinical Trials
- Diet and Physical Activity Change or Usual Care in Improving Progression-Free Survival in Patients With Previously Treated Stage II, III, or IV Ovarian, Fallopian Tube, or Primary Peritoneal Cancer Start of enrollment: 2012 Jun 18
- Evaluation of Carboplatin/Paclitaxel With and Without Trastuzumab (Herceptin) in Uterine Serous Cancer Start of enrollment: 2011 Jun 01
Publications & Presentations
PubMed
- 187 citationsDostarlimab for Primary Advanced or Recurrent Endometrial Cancer.Mansoor R Mirza, Dana M Chase, Brian M Slomovitz, René dePont Christensen, Zoltán Novák
The New England Journal of Medicine. 2023-06-08 - 152 citationsLinking cervicovaginal immune signatures, HPV and microbiota composition in cervical carcinogenesis in non-Hispanic and Hispanic women.Paweł Łaniewski, Dominique Barnes, Alison Goulder, Haiyan Cui, Denise J. Roe
Scientific Reports. 2018-05-15 - 5 citationsFactors associated with grade 3 or 4 treatment-related toxicity in women with advanced or recurrent cervical cancer: an exploratory analysis of NRG Oncology/Gynecologi...Dana M. Chase, James Kauderer, Lari Wenzel, Lois M. Ramondetta, David Cella
International Journal of Gynecological Cancer. 2015-02-01
Press Mentions
The Drug Zejula Shows Important Long-Term, Progression-Free Survival Benefit for Patients with Advanced Ovarian CancerOctober 13th, 2022- Bringing Discoveries to the Patient’s BedsideMarch 3rd, 2022
Analyses Underscore Extent of Frontline Maintenance Niraparib Benefit in Ovarian CancerApril 10th, 2020- Join now to see all
Professional Memberships
- Fellow
- Member
Other Languages
- Spanish
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence:
